| 56.455 0.225 (0.4%) | 10-28 15:08 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 67.31 | 1-year : | 78.62 |
| Resists | First : | 57.63 | Second : | 67.31 |
| Pivot price | 53.97  |
|||
| Supports | First : | 44.78 | Second : | 36.84 |
| MAs | MA(5) : | 54.63 |
MA(20) : | 50.4 |
| MA(100) : | 41.29 |
MA(250) : | 41.19 |
|
| MACD | MACD : | 4  |
Signal : | 4 |
| %K %D | K(14,3) : | 87.2 |
D(3) : | 82.6 |
| RSI | RSI(14): 68.6 |
|||
| 52-week | High : | 63.5 | Low : | 26.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APGE ] has closed below upper band by 24.6%. Bollinger Bands are 8.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 56.81 - 57.21 | 57.21 - 57.53 |
| Low: | 52.87 - 53.28 | 53.28 - 53.6 |
| Close: | 55.68 - 56.33 | 56.33 - 56.84 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Mon, 27 Oct 2025
Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know - TipRanks
Tue, 21 Oct 2025
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - Nasdaq
Tue, 21 Oct 2025
Assessing Apogee Therapeutics (APGE) Valuation Following Analyst Optimism on APG777’s Clinical Progress - Sahm
Fri, 17 Oct 2025
BTIG Maintains a Buy on Apogee Therapeutics (APGE) - Insider Monkey
Tue, 14 Oct 2025
Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? - Yahoo Finance
Thu, 09 Oct 2025
Why Apogee Therapeutics Stock Triumphed on Thursday - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 114.4 (%) |
| Shares Short | 8,550 (K) |
| Shares Short P.Month | 8,950 (K) |
| EPS | -4.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | -34.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -221 (M) |
| Levered Free Cash Flow | -139 (M) |
| PE Ratio | -13.61 |
| PEG Ratio | 0 |
| Price to Book value | 5.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|